A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Description

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

Conditions

ADHD

Study Overview

Study Details

Study overview

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Condition
ADHD
Intervention / Treatment

-

Contacts and Locations

Maitland

Accel Research Site-Maitland Clinical Research Unit, Maitland, Florida, United States, 32751

Decatur

iRresearch Atlanta, Decatur, Georgia, United States, 30030

Savannah

CenExel iRS - iResearch Savannah, Savannah, Georgia, United States, 31405

Boston

Boston Clinical Trials LLC, Boston, Massachusetts, United States, 02131

Las Vegas

Center For Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States, 89128

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    13 Years to 17 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Neurocentria, Inc.,

    Mary Miller, MS, STUDY_DIRECTOR, Neurocentria, Inc.

    Study Record Dates

    2025-11